Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation
-
Dmitriy V. Ivashchenko
,
Sofi Z. Khoang
,
Bakhu V. Makhmudova
,
Nina I. Buromskaya
Abstract
Objectives
Prediction of the antipsychotic’s effectiveness is a relevant topic in the field of personalized medicine.
Methods
The research design of this study is a prospective observation with posthoc analysis of associations of genetic polymorphisms with safety parameters and effectiveness of antipsychotic therapy. We observed 53 adolescents with an acute psychotic episode which were prescribed antipsychotics for 14 days. We evaluated the effectiveness of antipsychotics with the Positive and Negative Symptoms Scale and the safety with the UKU Side Effects Rating Scale, Simpson-Angus Scale, and Barnes Akathisia rating scale. We genotyped CYP3A4*22 (rs2740574), CYP3A5*3 (6986A>G, rs7767746), CYP2D6*4, *9, *10 (rs3892097, rs1065852), ABCB1 1236C>T (rs1128503), 2677G>T/A (rs2032582), 3435C>T (rs1045642), DRD2 (rs1800497), DRD4 (rs1800955), HTR2A (rs6313) by the real-time polymerase chain reaction method.
Results
We found significantly more frequent “increased dream activity” between CYP2D6 intermediate metabolizers and normal metabolizers (54 vs. 22%; p=0.043). The «increased duration of sleep» was more often observed in homozygotes TT of ABCB1 2677G>T/A (50 vs. 15.8%, p=0.006) and TT of 3435C>T (41.7 vs. 8.2%, p=0.007).
Conclusions
We found that CYP2D6 and ABCB1 polymorphisms were associated with the safety of antipsychotics in adolescents with an acute psychotic episode.
Funding source: Russian Science Foundation
Award Identifier / Grant number: 18-75-00046
Research funding: Research was supported by Grant No 18-75-00046 of the Russian Science Foundation.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The study was approved by the local ethics committees of Russian Medical Academy of Continuous Professional Education (Minutes No. 3 of 06 June 2018) and Scientific-Practical Children’s and Adolescents Mental Health Center n.a. G.E. Sukhareva (Minutes No. 2 of 14 June 2018). The study complied with the World Medical Association Declaration of Helsinki.
References
1. Masi, G, Liboni, F. Management of schizophrenia in children and adolescents. Drugs 2011;71:179–208. https://doi.org/10.2165/11585350-000000000-00000.Search in Google Scholar PubMed
2. Jerrell, JM, McIntyre, RS. Factors differentiating childhood-onset and adolescent-onset schizophrenia: a claims database study. Prim Care Companion CNS Disord 2016;18. https://doi.org/10.4088/pcc.15m01901.Search in Google Scholar
3. Remschmidt, H, Theisen, F. Early-onset schizophrenia1. Neuropsychobiology 2012;66:63–9. https://doi.org/10.1159/000338548.Search in Google Scholar PubMed
4. Schimmelmann, BG, Schmidt, SJ, Carbon, M, Correll, CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders. Curr Opin Psychiatry 2013;26:219–30. https://doi.org/10.1097/yco.0b013e32835dcc2a.Search in Google Scholar PubMed
5. Schneider, C, Corrigall, R, Hayes, D, Kyriakopoulos, M, Frangou, S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 2014;29:1–10. https://doi.org/10.1016/j.eurpsy.2013.08.001.Search in Google Scholar PubMed
6. Pagsberg, AK, Tarp, S, Glintborg, D, Stenstrøm, AD, Fink-Jensen, A, Correll, CU, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 2017;56:191–202. https://doi.org/10.1016/j.jaac.2016.12.013.Search in Google Scholar PubMed
7. Eum, S, Lee, AM, Bishop, JR. Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci 2016;18:323–37.10.31887/DCNS.2016.18.3/jbishopSearch in Google Scholar PubMed PubMed Central
8. Zhang, JP, Lencz, T, Malhotra, AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010;167:763–72. https://doi.org/10.1176/appi.ajp.2009.09040598.Search in Google Scholar PubMed PubMed Central
9. Takekita, Y, Fabbri, C, Kato, M, Koshikawa, Y, Tajika, A, Kinoshita, T, et al. HTR1A polymorphisms and clinical efficacy of antipsychotic drug treatment in schizophrenia: a meta-analysis. Int J Neuropsychopharmacol 2016;19:pyv125. https://doi.org/10.1093/ijnp/pyv125.Search in Google Scholar PubMed PubMed Central
10. Saiz-Rodríguez, M, Belmonte, C, Román, M, Ochoa, D, Jiang-Zheng, C, Koller, D, et al. Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol 2018;123:474–85. https://doi.org/10.1111/bcpt.13031.Search in Google Scholar PubMed
11. Wehry, AM, Ramsey, L, Dulemba, SE, Mossman, SA, Strawn, JR. Pharmacogenomic testing in child and adolescent psychiatry: an evidence-based review. Curr Probl Pediatr Adolesc Health Care 2018;48:40–9. https://doi.org/10.1016/j.cppeds.2017.12.003.Search in Google Scholar PubMed PubMed Central
12. Mas, S, Gassó, P, Torra, M, Bioque, M, Lobo, A, González-Pinto, A, et al. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. Eur Neuropsychopharmacol 2017;27:647–56. https://doi.org/10.1016/j.euroneuro.2017.03.012.Search in Google Scholar PubMed
13. Rafaniello, C, Sessa, M, Bernardi, FF, Pozzi, M, Cheli, S, Cattaneo, D, et al. The predictive value of ABCB1, ABCG2, CYP3A4/5, and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J 2018;18:422–30. https://doi.org/10.1038/tpj.2017.38.Search in Google Scholar PubMed
14. Ivanova, SA, Filipenko, ML, Vyalova, NM, Voronina, EN, Pozhidaev, IV, Osmanova, DZ, et al. CYP1A2 and CYP2D6 gene polymorphisms in schizophrenic patients with neuroleptic drug-induced side effects. Bull Exp Biol Med 2016;160:687–90. https://doi.org/10.1007/s10517-016-3250-4.Search in Google Scholar PubMed
15. Ito, T, Yamamoto, K, Ohsawa, F, Otsuka, I, Hishimoto, A, Sora, I, et al. Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study. J Pharm Heal Care Sci 2018;4:28. https://doi.org/10.1186/s40780-018-0126-y.Search in Google Scholar PubMed PubMed Central
16. Mi, W, Liu, F, Liu, Y, Du, B, Xiao, W, Li, L, et al. Association of ABCB1 gene polymorphisms with efficacy and adverse reaction to risperidone or paliperidone in han Chinese schizophrenic patients. Neurosci Bull 2016;32:547–9. https://doi.org/10.1007/s12264-016-0050-9.Search in Google Scholar PubMed PubMed Central
17. Pai, P, Arathil, P, Kotambail, A, Nair, R, Gupta, M, Moily, NS, et al. Association of GRIN1, ABCB1, and DRD4 genes and response to antipsychotic drug treatment in schizophrenia. Psychiatr Genet 2015;25:135–6. https://doi.org/10.1097/ypg.0000000000000079.Search in Google Scholar
18. Alladi, CG, RajKumar, RP, Adithan, S, Marie-Claire, C, Bellivier, F, Shewade, DG. Dopamine (DRD 2) and serotonin (HTR 2A, 2C) receptor gene polymorphisms do not influence early response to risperidone in South Indian patients with schizophrenia. Fundam Clin Pharmacol 2019;33:355–64. https://doi.org/10.1111/fcp.12424.Search in Google Scholar PubMed
19. Vehof, J, Burger, H, Wilffert, B, Al Hadithy, A, Alizadeh, BZ, Snieder, H, et al. Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. Eur Neuropsychopharmacol 2012;22:625–31. https://doi.org/10.1016/j.euroneuro.2012.01.006.Search in Google Scholar PubMed
20. Zanger, UM, Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103–41. https://doi.org/10.1016/j.pharmthera.2012.12.007.Search in Google Scholar PubMed
21. Xiang, Q, Zhao, X, Zhou, Y, Duan, JL, Cui, YM. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 2010;50:659–66. https://doi.org/10.1177/0091270009347867.Search in Google Scholar PubMed
22. Gardner, DM, Murphy, AL, O’Donnell, H, Centorrino, F, Baldessarini, RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010;:167686–93. https://doi.org/10.1176/appi.ajp.2009.09060802.Search in Google Scholar PubMed
23. Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;s334:1–100. https://doi.org/10.1111/j.1600-0447.1987.tb10566.x.Search in Google Scholar PubMed
24. Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11–9. https://doi.org/10.1111/j.1600-0447.1970.tb02066.x.Search in Google Scholar PubMed
25. Barnes, TRE. The Barnes akathisia rating scale–revisited. J Psychopharmacol 2003;17:365–70. https://doi.org/10.1177/0269881103174013.Search in Google Scholar PubMed
26. Kay, SR, Opler, LA, Spitzer, RL, Williams, JB, Fiszbein, A, Gorelick, A. SCID-PANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry 1991;32:355–61. https://doi.org/10.1016/0010-440x(91)90085-q.Search in Google Scholar PubMed
27. Zhou, Y, Ingelman-Sundberg, M, Lauschke, VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 2017;102:688–700. https://doi.org/10.1002/cpt.690.Search in Google Scholar PubMed PubMed Central
28. Gaedigk, A, Sangkuhl, K, Whirl-Carrillo, M, Klein, T, Leeder, JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 2017;19:69–76. https://doi.org/10.1038/gim.2016.80.Search in Google Scholar PubMed PubMed Central
29. Koning, JP, Vehof, J, Burger, H, Wilffert, B, Al Hadithy, A, Alizadeh, B, et al. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology 2012;219:727–36. https://doi.org/10.1007/s00213-011-2394-1.Search in Google Scholar PubMed
30. Mas, S, Gassó, P, Lafuente, A, Bioque, M, Lobo, A, Gonzàlez-Pinto, A, et al. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics J 2016;16:439–45. https://doi.org/10.1038/tpj.2016.44.Search in Google Scholar PubMed
31. van Westrhenen, R, Aitchison, KJ, Ingelman-Sundberg, M, Jukić, MM. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry 2020;11:94. https://doi.org/10.3389/fpsyt.2020.00094.Search in Google Scholar PubMed PubMed Central
32. Rodriguez, S, Gaunt, TR, Day, INM. Hardy–Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009;169:505–14. https://doi.org/10.1093/aje/kwn359.Search in Google Scholar PubMed PubMed Central
33. Sukasem, C, Vanwong, N, Srisawasdi, P, Ngamsamut, N, Nuntamool, N, Hongkaew, Y, et al. Pharmacogenetics of risperidone-induced insulin resistance in children and adolescents with autism spectrum disorder. Basic Clin Pharmacol Toxicol 2018;123:42–50. https://doi.org/10.1111/bcpt.12970.Search in Google Scholar PubMed
34. Savitz, J, Hodgkinson, CA, Martin-Soelch, C, Shen, PH, Szczepanik, J, Nugent, AC, et al. DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. Int J Neuropsychopharmacol 2013;16:2095–101. https://doi.org/10.1017/s146114571300045x.Search in Google Scholar PubMed PubMed Central
35. Kurylev, A, Brodyansky, V, Andreev, B, Kibitov, A, Limankin, O, Mosolov, S. The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study). Psychiatr Danub 2018;30:157–63. https://doi.org/10.24869/spsih.2018.157.Search in Google Scholar
36. Ikeda, M, Yamanouchi, Y, Kinoshita, Y, Kitajima, T, Yoshimura, R, Hashimoto, S, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008;9:1437–43. https://doi.org/10.2217/14622416.9.10.1437.Search in Google Scholar PubMed
37. Escamilla, R, Camarena, B, Saracco, R, Fresán, A, Hernández, S, Aguilar-García, A. Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia. Neuropsychiatr Dis Treat 2018;14:2981–7. https://doi.org/10.2147/ndt.s176455.Search in Google Scholar
38. Kang, SG, Na, KS, Lee, HJ, Chee, IS, Lee, K, Lee, J. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks’ amisulpride treatment. J Clin Psychopharmacol 2015;35:158–62. https://doi.org/10.1097/jcp.0000000000000294.Search in Google Scholar
39. Chen, SF, Shen, YC, Chen, CH. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology 2009;205:285–92. https://doi.org/10.1007/s00213-009-1538-z.Search in Google Scholar PubMed
40. Sosin, D, Ivashchenko, D, Sozaeva, Z, Ryzhikova, K, Fadeeva, V, Chomskaya, V, et al. Cognitive impairment in patients with treatment resistant schizophrenia: associations with DRD2, DRD3, HTR2A, BDNF, and CYP2D6 genetic polymorphisms. Neurol Psychiatry Brain Res 2019;33:48–55. https://doi.org/10.1016/j.npbr.2019.06.003.Search in Google Scholar
41. Kim, B, Choi, EY, Kim, CY, Song, K, Joo, YH. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol Clin Exp 2008;23:61–7. https://doi.org/10.1002/hup.897.Search in Google Scholar PubMed
42. Jovanović, N, Božina, N, Lovrić, M, Medved, V, Jakovljević, M, Peleš, AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 2010;66:1109–17. https://doi.org/10.1007/s00228-010-0850-1.Search in Google Scholar PubMed
© 2020 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Editorial
- The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What’s next? An urgent clinical unmet need for patients
- Review
- Understanding COVID-19 in the light of epidemic disease described in Unani medicine
- Original Articles
- Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation
- Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders
- A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods
- Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans
- Prognostic indicators in critically ill poisoned patients: development of a risk-prediction nomogram
- Related expression of TRKA and P75 receptors and the changing copy number of MYC-oncogenes determine the sensitivity of brain tumor cells to the treatment of the nerve growth factor in combination with cisplatin and temozolomide
- Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin
- Methyl jasmonate delays the latency to anoxic convulsions by normalizing the brain levels of oxidative stress biomarkers and serum corticosterone contents in mice with repeated anoxic stress
- Diosmin attenuates schizophrenia-like behavior, oxidative stress, and acetylcholinesterase activity in mice
- Case Report
- NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series
Articles in the same Issue
- Editorial
- The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What’s next? An urgent clinical unmet need for patients
- Review
- Understanding COVID-19 in the light of epidemic disease described in Unani medicine
- Original Articles
- Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation
- Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders
- A study of the pharmacokinetics of moxifloxacin by the dynamics of its distribution in the blood plasma and saliva of healthy volunteers: a comparative analysis and possible extrapolation methods
- Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans
- Prognostic indicators in critically ill poisoned patients: development of a risk-prediction nomogram
- Related expression of TRKA and P75 receptors and the changing copy number of MYC-oncogenes determine the sensitivity of brain tumor cells to the treatment of the nerve growth factor in combination with cisplatin and temozolomide
- Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin
- Methyl jasmonate delays the latency to anoxic convulsions by normalizing the brain levels of oxidative stress biomarkers and serum corticosterone contents in mice with repeated anoxic stress
- Diosmin attenuates schizophrenia-like behavior, oxidative stress, and acetylcholinesterase activity in mice
- Case Report
- NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series
